Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GENPREX INC (GNPX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.10-1.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GNPX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce negative cash from operations to about -$3.14M per quarter | Cash burn has improved from negative $5.8M to negative $3.14M per quarter. | Broken | cash burn worsens below -$4M per quarter next year | Cash from operations: $-5.139M FY2026-Q2; GAAP. Published target: cash from operations >= -$3.14M per quarter. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-5,138,699 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not an established earnings compounder. The multi-year thesis is in a watch state: research milestones and intellectual-property work offer support, but execution is behind and the evidence snapshot has low confidence.
The snapshot provides no valuation measure or specific evidence about market expectations, so whether GNPX is cheap, fair, or expensive versus peers cannot be assessed. Its recent price reaction was down, but the evidence does not show what expectations are already reflected.
Near term, persistent operating losses, worsening cash from operations, and erratic earnings surprises point to continued financial strain and elevated risk of a quarterly miss. Over the multi-year view, Reqorsa Gene Therapy development remains central, but there is no reported revenue and management is behind on this priority.
The thesis hinges on clinical development progress, the ability to manage cash burn, and whether patent work can support the program despite no reported commercial revenue. Near-term sector conditions could help or hurt sentiment: stronger results from healthcare bellwethers may sustain the sector tailwind, while weaker jobs data or bellweller misses could weaken it.
Over the next 1 to 3 years, GNPX remains a high-risk watch thesis with limited evidence of financial progress and important clinical and cash-flow questions. Recent partnership news is positive, but litigation and the earlier listing-rule notice add uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn.
Advance clinical development of Reqorsa Gene Therapy | Genprex is advancing clinical research on its cancer gene therapy. | Under Pressure | progress score falls below 30% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 4 of last 4 quarters. While no revenue is reported, management has consistently emphasized advancing clinical development through collaborations and patent expansions. The trajectory shows persistent focus with positive research milestones but no commercial revenue yet. Delivery assessment Oct 31, 2026 |
Protect and expand IP portfolio for gene therapy products | Genprex is advancing clinical research on its cancer gene therapy. | Intact | loss of key patents or IP rights | Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 4 quarters. Management has secured multiple patents expanding the intellectual property portfolio for Reqorsa Gene Therapy. While no direct financial impact is reported, the company is actively protecting and expanding IP rights, showing consistent delivery on this priority. Delivery assessment Oct 31, 2026 |
Manage operating losses near $4.46M per quarter | The company is working to control losses around $4.46M per quarter. | Broken | net loss exceeds $5M per quarter next year | Net income: $-4.447M FY2026-Q2; GAAP. Published target: net loss <= $4.46M per quarter. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-4,447,219 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn. Delivery assessment Oct 31, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-10560.00 → $-10560.00 · observed estimates
FY2027 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-25 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-26 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-27 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-28 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-29 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-30 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-07-31 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-01 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-02 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-03 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-04 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-05 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-06 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-07 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-08 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-09 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-10 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-12 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-13 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-14 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-15 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-16 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-17 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-18 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-19 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-20 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-21 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-22 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-23 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-24 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-25 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-26 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-27 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-28 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-29 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-30 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-08-31 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-01 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-02 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-03 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-04 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-05 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-06 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-07 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-08 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-09 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-10 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-11 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-12 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-13 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-14 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-15 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-16 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-17 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-18 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-19 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-20 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-21 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-22 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-23 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-24 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-25 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-26 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-27 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-28 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-29 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-09-30 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-01 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-02 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-03 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-04 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-05 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-06 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-07 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-08 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-09 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-10 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-11 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-12 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-13 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-14 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-15 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-16 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-17 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-18 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-19 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-20 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-21 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-22 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-23 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-24 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-25 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-26 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-27 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-28 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-29 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-30 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-10-31 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-11-01 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-11-02 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-11-03 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-11-04 | $-10560.00 | Unavailable | 1 / 0 |
| 2026-11-05 | $-10560.00 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.